BMY - Bristol Myers' REBLOZYL wins Health Canada approval for transfusion-dependent anemia

Bristol Myers Squibb Company ([[BMY]] -0.2%) Bristol Myers Squibb Canada and Acceleron Pharma ([[XLRN]] -2.6%)announce that Health Canada has approved REBLOZYL (luspatercept for injection) for the treatment of certain patients with transfusion-dependent anemia. The approval is for use in treating patients requiring at least two RBC red blood cell ((RBC)) units over 8 weeks resulting from very low-to intermediate-risk myelodysplastic syndromes ((MDS)) who have ring sideroblasts and who have failed or are not suitable for erythropoietin-based therapy.MDS are a group of cancers which cause limitations in the bone marrow’s ability to produce healthy and mature RBCs, and typically occur among older people."Treatment options to remedy transfusion dependence are limited once first line therapy fails, so REBLOZYL, as the only erythroid maturation agent in Canada, provides an important MDS treatment to achieve RBC transfusion independence in a subgroup of patients," Rena Buckstein associate professor and Head of the Hematology Disease Site Group at Odette Cancer Centre said.Health

For further details see:

Bristol Myers' REBLOZYL wins Health Canada approval for transfusion-dependent anemia